Astronics (ATRO) Q4 2006 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2006 earnings summary
5 Nov, 2026Executive summary
FY06 revenue rose 48.9% to $110.8M and diluted EPS increased to $0.69 from $0.28, on strong aerospace demand and higher product content per aircraft.
Results benefited most from commercial transport and business jet growth; management expected 2007 revenue of $135M–$140M.
Financial highlights
Revenue was $110.767M vs. $74.354M in FY05; net income was $5.736M vs. $2.237M.
Diluted EPS was $0.69 vs. $0.28; income from continuing operations represented 5.2% of sales vs. 3.0% in FY05.
FY06 operating cash flow was negative $0.047M vs. positive $5.015M in FY05, as sales-driven working-capital investment absorbed cash.
Outlook and guidance
FY07 revenue guidance was $135M–$140M; a separate outlook projection cited $140M, assuming continued strength in the global aerospace economy.
Year-end backlog was $99.5M, with approximately $85M expected to ship during 2007; backlog was $96.1M at FY05 year-end.
Management expected engineering and development spending to remain comparable to FY06, with spending more aligned to revenue growth.
Latest events from Astronics
- Record Q3 results and backlog support 2027 growth despite supply and timing risks.ATRO
Q3 2026 - Record earnings and a $40.198M backlog supported a strong 2000 shipment outlook.ATRO
Q4 1999 - Record growth led by F-16 demand; 2001 sales target exceeded $85M.ATRO
Q4 2000 - Record 2001 results met weakening demand as F-16 production neared its end.ATRO
Q4 2001 - F-16 sales faded, but stable margins and the JSF award shaped the next growth phase.ATRO
Q4 2002 - F-16 completion pressured 2003 results, while new design wins built a growth pipeline.ATRO
Q4 2003 - Higher development spending drove a 2004 loss as backlog and AES set up 2005 growth.ATRO
Q4 2004 - FY05 sales surged 117%; $95.1M backlog supports growth, tempered by certification risks.ATRO
Q4 2005 - Sales grew, but Eclipse charges cut FY08 earnings as DME reshaped the FY09 outlook.ATRO
Q4 2008